Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode hundreds of pages of oncology jargon in Processa Pharmaceuticals’ filings? Each Form 10-K outlines how the company funds its Next Generation Chemotherapy (NGC) pipeline, while every 8-K details new clinical milestones or FDA feedback that can move PCSA’s share price overnight. Missing one paragraph could mean overlooking a cash-raising shelf registration or a trial setback.
StockTitan’s AI reads the documents for you. Our platform delivers plain-English summaries of the Processa Pharmaceuticals annual report 10-K simplified, highlights R&D spending trends in the latest Processa Pharmaceuticals quarterly earnings report 10-Q filing, and flags dilution risks buried in S-3 prospectuses. Need real-time alerts? We stream Processa Pharmaceuticals Form 4 insider transactions as soon as they hit EDGAR, so you can track executive confidence without wading through pdfs.
Use our guided view to jump straight to the sections investors ask about most:
- Cash runway projections and trial budgets in 10-Q MD&A
- NGC clinical results and FDA responses in 8-K material events explained
- Processa Pharmaceuticals insider trading Form 4 transactions with AI-generated context on each buy or sell
- Board pay packages inside the Processa Pharmaceuticals proxy statement executive compensation
Whether you’re asking “How do I read Processa’s 10-K?” or searching for “understanding Processa Pharmaceuticals SEC documents with AI,” StockTitan delivers every filing type—10-K, 10-Q, 8-K, S-3, SC 13G, and more—complete with expert notes and real-time updates. Spend minutes, not hours, turning dense biotech disclosures into actionable insight.
Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA) discloses an equity award to insider David Young, the company’s President, R&D and a director.
- Transaction date: 07/24/2025
- Security: 1,813,133 restricted stock units (RSUs) granted at $0 exercise price under the 2019 Omnibus Incentive Plan.
- Contingency: 1,790,833 of the RSUs require stockholder approval of the revised Omnibus Plan.
- Vesting schedule: One-third vests 01/01/2026; the balance vests monthly in equal installments through 01/01/2028 (one-thirty-sixth per month).
- Post-grant holdings: Young now beneficially owns 1,821,016 derivative securities.
- Ownership type: Direct.
No non-derivative transactions were reported and no sale or disposition occurred. The filing only records the RSU grant and the associated vesting and approval conditions.
Processa Pharmaceuticals (PCSA) – Form 4 Insider Filing
On 24 Jul 2025, Chief Executive Officer & Director George K. Ng received 1,822,471 Restricted Stock Units (RSUs) under the 2019 Omnibus Incentive Plan at a $0 exercise price. Each RSU converts into one common share as follows: one-third vests on 1 Jan 2026 and the remainder vests monthly through 1 Jan 2028. Footnote 1 states that 1,859,318 of the underlying shares are contingent on stockholder approval of a revised plan.
After the grant, Ng beneficially owns 1,922,471 derivative securities linked to PCSA common stock, all held directly. No open-market purchases or sales were reported; the transaction reflects an equity-based compensation award that could add up to roughly 1.8 million new shares to the float once vested and, where applicable, approved.
FAQ
What is the current stock price of Processa Pharmaceuticals (PCSA)?
What is the market cap of Processa Pharmaceuticals (PCSA)?
